Depot Medroxyprogesterone and Meningioma Risk | Neuro ...
Sep 2, 2025 · Meningiomas are the most frequent primary brain tumors and the majority are benign. 1 The annual incidence is low: 6 to 8 new cases per 100 000 with a peak in middle-aged patients. 2 …
Depot Medroxyprogesterone Acetate and Risk of Meningioma in ...
Nov 1, 2025 · In this study, women receiving depot medroxyprogesterone acetate had a greater relative risk of subsequent meningioma diagnosis, especially with prolonged exposures and starting the …
Counseling Patients on Birth Control Injection and Meningioma
Learn about the recent study on birth control injections and meningioma risk, and how shared decision-making empowers patients to make informed choices.
Use of progestogens and the risk of intracranial meningioma ...
Mar 27, 2024 · To our knowledge, this study of meningioma risk is the first to expand the list of progestogens of interest beyond chlormadinone acetate, nomegestrol acetate, and cyproterone …
Study Reveals 143% Higher Risk of Brain Tumors With Long-Term ...
Sep 4, 2025 · Women who used dMPA for four to six years faced a 200% higher risk of meningioma, and those who continued beyond six years experienced a 290% higher risk. This suggests that the …
Jun 26, 2025 · CONCLUSION: The current results are consistent with the prior literature that dMPA exposure is associated with an increased likelihood of meningioma for prolonged use. More research …
Medroxyprogesterone acetate and meningioma: a global issue
Mar 26, 2025 · Then, in 2021, studies found a strong association between the risk of meningioma and the use of two other potent progestogens, nomegestrol and chlormadinone acetate, mainly …